| Unknown | Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye NCT01217398 | Institut Curie | Phase 2 |
| Completed | Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye NCT00952939 | Case Comprehensive Cancer Center | — |
| Completed | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by S NCT00471471 | Ahmad Tarhini | Phase 1 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Ey NCT00738361 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Advanced Melanoma NCT00705640 | Craig L Slingluff, Jr | Phase 1 |
| Unknown | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the NCT00757614 | Cancer Research UK | — |
| Completed | Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma NCT00897624 | Institut Curie | — |
| Unknown | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma NCT00489944 | San Diego Pacific Oncology & Hematology Associates | Phase 2 |
| Terminated | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma NCT00482911 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation NCT00471133 | Ichor Medical Systems Incorporated | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma NCT00398073 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Dendritic Cell Vaccination During Lymphoid Reconstruction NCT00313508 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable NCT00324727 | Delcath Systems Inc. | Phase 3 |
| Completed | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma NCT00243061 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal NCT00445965 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastase NCT00110123 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melan NCT00084656 | Bristol-Myers Squibb | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00334776 | University of Southern California | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma NCT00089219 | University of Virginia | Phase 1 / Phase 2 |
| Completed | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00072345 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00058279 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00089206 | University of Virginia | Phase 2 |
| Completed | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Me NCT00031733 | University of Southern California | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Melanoma of the Eye NCT00036816 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma NCT00032045 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been NCT00025181 | University of Southern California | Phase 1 |
| Completed | Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma NCT00027742 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma NCT00238329 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00005841 | University of Southern California | Phase 1 |
| Completed | Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma NCT00005815 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma NCT00003802 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma NCT00003339 | University of Southern California | Phase 2 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer NCT00003022 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer NCT00002947 | Yale University | Phase 1 |